Skip to main content

Advertisement

Table 4 Main findings on HRQoL in RCTs

From: Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review

Comp.: Study Key Findings Potential Limitation(s)
S1a Donovan,
J L/
2016 [37]
Comparison: AS vs. RP vs. EBRT, follow-up timeb: 5-6 years, mean agec: 62 years
- No significant differences were observed among intervention groups in measures of general health-related or cancer-related quality of life
 
S1 Giberti, C/ 2009 [41] Comparison: RP vs. BT, follow-up timeb: 5 years, mean agec: 65.3 years
- No significant differences were observed among intervention groups in measures of general health-related or cancer-related quality of life
- Sample size <100 in both study arms
- No intention to treat analyses
S2 Brundage, M/ 2015 [36] Comparison: ADT vs. ADT + EBRT, follow-up timeb: 5-8 years, median agec: 69.7 years
- No significant between-arm differences in physical or role functioning at any time point 5+ years after diagnosis
- Significant (p < 0.001) deterioration in both arms over time for physical and role functioning
- Sample size <100 in both study arms
- Only results on physical and role functioning were reported for this follow-up time
  1. Comp. Comparison group
  2. S1: HRQoL by primary intervention in long-term survivors with localized PC; S2: HRQoL by intervention in long-term survivors with locally advanced PC; S3: HRQoL by intervention in long-term survivors with localized or locally advanced PC
  3. Studies were ordered by stage information and within each group alphabetically
  4. As potential limitation following criteria were considered: (1) sample size 100 per study arm for studies using EORTC-C30 and 70 for studies using SF-36 (2) randomization (3) intention to-treat analyses (4) reporting of results appropriate
  5. aInlcusion of PC survivors with disease progression
  6. bTime since randomization
  7. cAge at randomization